Platelet activation by thrombin is critical for hemostasis and thrombosis. Structure-function studies with a recently cloned platelet thrombin receptor suggest that a hirudin-like domain in the receptor's extracellular amino terminal extension is a thrombin-binding determinant important for receptor activation. We now report that a peptide antiserum to this domain is a potent and specific antagonist of thrombin-induced platelet activation. This study demonstrates that the cloned platelet thrombin receptor is necessary for platelet activation by thrombin, and provides a strategy for developing blocking monoclonal antibodies of potential therapeutic value. (J. Clin. Invest. 1992. 
Introduction
Thrombin-induced platelet activation plays a pivotal role in arterial thrombosis (1, 2) . We recently isolated a cDNA clone encoding a functional platelet thrombin receptor (3) . The clone encoded a member ofthe seven transmembrane span family of receptors with a 100-residue amino terminal extension. The amino acid sequence of this extracellular extension revealed a thrombin cleavage site (LDPR/S with/representing the point of cleavage) and a "hirudin-like domain" (DKYEPFWEDEE). Structure-function studies with the cloned receptor and receptor-based peptides suggest the following model ofreceptor activation. Thrombin binds its receptor via at least two sites: thrombin's S1-S4 subsites interact with the receptor's thrombin cleavage site (LDPR/S), while thrombin's anion-binding exosite interacts with the receptor's hirudin-like domain (4, 5) . Thrombin then cleaves the receptor at the LDPR/S site, unmasking a new receptor amino terminus beginning with the sequence SFLL ... ; this new amino terminus then functions as a tethered peptide ligand to effect receptor activation (3) . A synthetic peptide mimicking this new amino terminus functioned as a full agonist for platelet activation (3), suggesting that activation ofthe cloned receptor or a highly related receptor was sufficient for platelet activation.
Is the cloned platelet thrombin receptor necessary for platelet activation by thrombin? We now report that a peptide antiserum to the receptor's hirudin-like domain specifically blocks thrombin-induced responses in platelets. These studies show that activation ofthe cloned thrombin receptor is indeed necessary for platelet activation by thrombin, and buttress the importance ofthe receptor's hirudin-like domain in thrombin-receptor interactions. Moreover Fig. 1 A) . Rabbit polyclonal antisera were raised to peptides 359-1 and 360-1 conjugated by maleido-bis-succinimide to keyhole limpet hemocyanin (KLH) (6) . Antisera were screened initially by ELISA against antigen and irrelevant peptides (6) , then by immunoblot (see Fig. 1 B) . All platelet and oocyte experiments used IgG purified from immune or preimmune sera, using protein-A agarose (Pierce Chemical Co., Rockford, IL) and dialysis against phosphate-buffered saline. Stably transfected Rat 1 cells expressing the cloned human platelet thrombin receptor were prepared by standard techniques (7) . Antiserum raised to KLH-conjugated peptide 360-1 is referred to as "hirudin-like domain antiserum." IgG purified from this antiserum is referred to as "hirudin-like domain IgG." Preimmune sera and "irrelevant" peptide antiserum raised to monocyte chemoattractant protein were used as controls.
Platelet aggregation and ATP secretion studies. Washed platelets were prepared as previously described (8) , and unless otherwise noted, were suspended in modified Tyrode's buffer, pH 7.4 with 2 mM magnesium and 1 mM calcium at a concentration of 3 X 10' platelets/ml.
All platelet studies were performed in a total volume of 500 ;d, with 20 ;Il Chromolumes reagent (Chrono-log Corp., Havertown, PA). Platelet ATP secretion and aggregation were quantitated independently by measuring changes in luminescence and light transmittance, respectively, in a dual-channel lumiaggregometer (Chrono-log Corp.) (9) . Stirred platelets were used to ensure rapid and uniform distribution of agonist, and initial rates ofsecretion were determined as defined in the appropriate figure legends.
Xenopus oocyte studies. Xenopus oocytes were harvested from female Xenopus laevis and processed using published techniques (10, 11) . Individual oocytes were microinjected with cloned functional platelet thrombin receptor cRNA and cultured for 48 h at 18'C in modified Barth's solution (3). Thrombin-or agonist peptide-induced calcium mobilization was measured by 45Ca release from receptor-expressing oocytes (3, 11) .
Results and Discussion
The importance of the thrombin receptor's hirudin-like domain in thrombin-receptor interaction (4, 5) suggested that an antiserum to this domain might block receptor activation by thrombin. Accordingly, we raised rabbit antiserum to a peptide representing this domain; IgG purified from this antiserum was used for these studies.
The hirudin-like domain antiserum recognized a broad band at 70 kD in immunoblots of lysate from mammalian cells transfected with thrombin receptor cDNA ( Fig. 1 B) . This concentration of thrombin typically gives EC50 or greater platelet responses. Platelet ATP secretion and platelet aggregation were measured in a lumiaggregometer (9) . In panel C, platelets were pretreated with hirudin-like domain or control IgG and challenged with the concentrations ofthrombin indicated, and platelet ATP secretion was measured. Points represent the mean ofthe peak ATP secretion noted at each thrombin concentration indicated in three replicate determinations. Platelet ATP secretion and aggregation data in all experiments are expressed as a percentage of maximum; 100% ATP secretion is defined as the peak luminescence signal obtained after the addition of 100 nM a-thrombin to control IgG-pretreated platelets; 100% aggregation is defined as the light transmission obtained 2.5 min after the addition of 100 nM a-thrombin to control IgG-pretreated platelets. All experiments were replicated at least three times. tion in response to thrombin (1 nM), agonist peptide SFLLRNPNDKYEPF (30 ,M), and A23187 (60 nM) was measured as described in Fig. 2 but did not block platelet responses to EC_0, or even lower concentrations of thrombin receptor agonist peptide (Fig. 3) . Thrombin receptors on antibody-treated platelets are thus available for activation by agonist peptide, which bypasses receptor proteolysis and activates the thrombin receptor directly (3, 4) . The ability of the hirudin-like domain IgG to block thrombin-but not agonist peptide-induced platelet activation suggests that the hirudin-like domain IgG does act by specifically binding the receptor's hirudin-like domain, thereby blocking thrombin interaction with the receptor's amino terminal extension, but not agonist peptide interaction with the body ofthe receptor. The specificity ofthe antiserum is further confirmed by its inability to block platelet activation by sub-EC_, concentrations of calcium ionophore (Fig. 3) .
The inhibitory effects ofthe hirudin-like domain IgG preparation were ablated by preincubating the IgG with the peptide to which it was raised (peptide 360, Fig. 4 ), but not by preincubation with an unrelated peptide (peptide 359, Fig. 4 ). These data strongly suggest that the inhibitory activity ofthis preparation is due to antibodies that recognize the thrombin receptor's hirudin-like domain.
To further test the importance ofthe receptor's hirudin-like domain in the action ofthis antiserum, a mutant receptor lacking this domain was expressed in Xenopus oocytes and thrombin responses assessed. Deletion of the receptor's hirudin-like domain caused the concentration response to thrombin to shift rightward, but had no significant effect on the concentration response to peptide (4). Hirudin-like domain IgG inhibited thrombin-induced calcium mobilization in oocytes expressing the wild-type thrombin receptor, right shifting the concentration response curve by -30-fold and toward that seen for deletion mutant receptor (A51-63; Fig. 5) . Moreover, the receptor's hirudin-like domain was indeed required for the inhibition by the hirudin-like domain antiserum, in that the antiserum did not inhibit thrombin responses in oocytes expressing the A5 1-63 receptor (Fig. 5 ).
Similar studies with multiple different antisera to various receptor domains support the role of the cloned receptor in thrombin-induced platelet activation (not shown). IgG from three different rabbit antisera raised to the receptor's hirudinlike domain peptide (peptide 360-1, Fig. 1 A) Fig. 1 A) . IgG from two of these antisera blocked thrombin-induced platelet activation, but less effectively than the hirudin-like domain antisera. Prevention ofagonist peptide function or of receptor cleavage by antibody binding at or near this sequence may account for the activity of the inhibitory 359-1 antisera.
IgG from a third antiserum to peptide 359-1 had no inhibitory activity at up to 30 Aig/ml, nor did IgG from two other antisera raised to a peptide representing the thrombin receptor's second extracellular loop. In the absence of information on the fraction ofreceptor's occupied by antibody on the intact platelet, these negative data cannot be used to draw conclusions regarding specific structure-function issues; such studies will become possible when receptor monoclonal antibodies are available. These data do suggest, however, that blocking activity may not be a general feature of all receptor antisera. In summary, these studies strongly demonstrate that an antiserum to the cloned thrombin receptor's hirudin-like domain blocks thrombin-induced platelet activation. Previous reports have suggested that activation ofthe cloned thrombin receptor is sufficient for platelet activation by showing that thrombin receptor agonist peptide mimics thrombin-induced platelet secretion and aggregation (3) and thrombin-induced phosphoinositide signaling ( 17) . The present study now "closes the loop" on the clone; the demonstration that peptide antisera to the cloned thrombin receptor block thrombin-induced platelet activation now strongly suggests that the cloned receptor is necessary for platelet activation by thrombin. This result does not preclude a role for other thrombin receptors or binding proteins in platelet activation ( 12) , but implies that such receptors would play an adjunctive rather than central role.
Mutation of the thrombin receptor's hirudin-like domain by deletions or by alanine scanning suggested the importance of this domain in receptor activation by thrombin (4). Receptor peptides representing this domain directly bind thrombin, apparently by interacting with thrombin's anion-binding exosite (5) . The inhibitory activity ofthe hirudin-like domain antiserum buttresses these studies by providing functional evidence for the importance of the thrombin receptor's hirudinlike domain in intact platelets.
The effectiveness with which this polyclonal antiserum blocks thrombin-induced platelet activation establishes the cloned thrombin receptor as a potential target for antiplatelet therapy as well as the feasibility of developing antibody-based thrombin receptor antagonists. Blocking monoclonal antibodies to the receptor's hirudin-like domain or other domains will be valuable reagents for establishing the role of thrombin receptor activation in various in vivo processes. Such antibodies may be of therapeutic value as antithrombotic agents or as antagonists of thrombin's inflammatory (13, 14) , or proliferative actions ( 15, 16) .
